Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer is a phase 2, interventional study registered as NCT05706779 by Federation Francophone de Cancerologie Digestive, with a registry enrolment figure of 30 participants, started 2023-02-13 and due to reach its primary completion in 2026-12-30. Interventions recorded: Encorafenib Oral Capsule + Cetuximab. Conditions listed: Colorectal Cancer; BRAF V600E Mutation Positive. Primary outcome: To assess the rate of significant tumour regression (TRG 0 to 2 according to Ryan's modified score of the AJCC 2010). Colorectal eligibility wording from the registry: "* Adenocarcinoma of the colon or of the upper rectum (supra-peritoneal) considered operable and histologically confirmed, localised, mutated BRAF V600E determined in a biopsy specimen and resectable after CT-scan assessment". Sites: France. No results are recorded here; the registry entry is the source.